Luca Fabris, MD, PhD
Associate Professor Adjunct of Medicine (Digestive Diseases), Internal MedicineAbout
Titles
Associate Professor Adjunct of Medicine (Digestive Diseases), Internal Medicine
Appointments
Digestive Diseases
Associate Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of Milan (1997)
- MD
- University of Padova (1987)
Research
Publications
2024
Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management
Fabris L, Pol J. Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management. Gut 2024, 73: 1229-1231. PMID: 38631898, DOI: 10.1136/gutjnl-2024-332288.Peer-Reviewed Original ResearchSex and Gender in Ageing and Longevity: Highlights From an International Course
Candore G, Accardi G, Aiello A, Baggio G, Bellini T, Calabrese V, Carreca A, Carreca I, Masucci A, Cattaneo M, Dato S, Bona D, Fabris L, Gambino C, Lorenzo G, Franceschi C, Ligotti M, Manfrinato M, Puca A, Tamburello M, Vassallo R, Caruso C. Sex and Gender in Ageing and Longevity: Highlights From an International Course. Translational Medicine UniSa 2024, 26: 15-29. PMID: 38560614, PMCID: PMC10980291, DOI: 10.37825/2239-9747.1049.Peer-Reviewed Original Research
2023
Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids
Romanzi A, Milosa F, Marcelli G, Critelli R, Lasagni S, Gigante I, Dituri F, Schepis F, Cadamuro M, Giannelli G, Fabris L, Villa E. Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids. Biomedicines 2023, 12: 87. PMID: 38255193, PMCID: PMC10813100, DOI: 10.3390/biomedicines12010087.Peer-Reviewed Original ResearchThe evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
Fabris L, Campello E, Cadamuro M, Simioni P. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2023, 1870: 166763. PMID: 37951510, DOI: 10.1016/j.bbadis.2023.166763.Peer-Reviewed Original ResearchMetabolic dysfunction-associated fatty liver diseaseFatty liver diseaseCardiovascular diseaseLiver diseaseInsulin resistanceLiver fibrosisMajor public health problemPublic health problemMAFLD patientsMAFLD progressionCardiometabolic riskMetabolic syndromeOverall mortalityHepatic repairHepatic fibrogenesisHepatic componentGeneral populationTherapeutic targetingHealth problemsTranslational potentialFibrosisDiseaseGenetic factorsRisk profilingStrongest predictorThe tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts
Cadamuro M, Nuozzi G, Simioni P, Fabris L. The tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts. Hepatoma Research 2023, 9: null-null. DOI: 10.20517/2394-5079.2023.94.Peer-Reviewed Original ResearchCancer-associated fibroblastsHepatocellular carcinomaTumor microenvironmentCommon primary liver malignancyFibro-inflammatory conditionPrimary liver malignancyLimited effective treatmentsWorrisome diseaseLiver malignanciesAggressive tumorsEffective treatmentAggressive phenotypeNeoplastic diseaseCell originCirrhotic backgroundEpithelial compartmentTranslational valueSpecific populationsNeoplastic transformationTumorsDiseasePossible ameliorationCell typesRecent findingsFibroblastsFXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH
Di Pasqua L, Cagna M, Palladini G, Croce A, Cadamuro M, Fabris L, Perlini S, Adorini L, Ferrigno A, Vairetti M. FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH. Liver International 2023, 44: 214-227. PMID: 37904642, DOI: 10.1111/liv.15767.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisHigh-fat dietOb/ob mouse modelObeticholic acidAgonist obeticholic acidSerum alanine transaminaseAlanine transaminaseMMP-2MMP-9Mouse modelCollagen depositionHepatic ischaemia/reperfusion injuryFarnesoid X receptor agonist obeticholic acidControl dietFXR agonist obeticholic acidIschaemia/reperfusion injuryHepatic stellate cell activationMMP-9 activityStellate cell activationMMP-2 expressionΑ-SMA levelsOCA administrationHFD groupReperfusion injuryLiver steatosis